Skip to content

Topical and interventional treatment

TL;DR — Topical treatment is most rational for localized peripheral neuropathic pain with intact skin. High-concentration capsaicin has modest efficacy (NeuPSIG NNT 10.6 for 50% relief), while randomized lidocaine evidence is very low quality (Finnerup 2015, PMID 25575710); (Derry 2014, PMID 25058164). Interventional procedures require anatomically coherent targets and explicit procedural-risk accounting.

Lidocaine

Low systemic exposure is attractive, but Cochrane found no high-quality evidence; apparent clinical tolerability should not be confused with proven efficacy (Derry 2014, PMID 25058164).

The evidence problem is not the absence of any positive study; it is that small, short, incompletely blinded crossover studies do not yield a stable estimate. The Cochrane review included 12 studies/508 participants, but only one first-treatment-period parallel comparison contributed to the primary efficacy analysis, and evidence quality was very low (Derry 2014, PMID 25058164). Lidocaine's favorable systemic safety can justify an individualized trial in localized peripheral pain without converting tolerability into a strong efficacy recommendation.

Capsaicin

Capsaicin 8% defunctionalizes TRPV1-expressing terminals after supervised application; Cochrane supports a minority response with application pain (Derry 2017, PMID 28085183).

In a 369-person painful diabetic peripheral neuropathy RCT, one 30-minute application reduced average daily pain by 27.4% versus 20.9% with placebo over weeks 2–8 (P=0.025); median time to response was 19 versus 72 days, and sensory testing did not show deterioration over 12 weeks (Simpson 2017, PMID 27746370). The absolute placebo-adjusted mean difference was small, consistent with the cross-etiology NNT of 10.6 for 50% relief (Finnerup 2015, PMID 25575710).

An open-label randomized comparison in 559 non-diabetic participants found capsaicin noninferior to pregabalin at eight weeks. Patient-reported cognition favored capsaicin by 4.28 points (95% CI 2.90–5.66), EQ-VAS by 3.11 (95% CI 0.30–5.92), and treatment satisfaction by 6.74 (95% CI 2.29–11.20), but lack of blinding limits comparative inference (Viel 2021, PMID 34554688).

Topical question Best current answer Residual uncertainty
Who is anatomically eligible? Pain should be superficial, localized and accessible on intact skin “Localized” lacks a universally validated area threshold
How large is capsaicin benefit? PDN mean reduction 27.4% versus 20.9% placebo over weeks 2–8 (Simpson 2017, PMID 27746370) Long-term repeated-treatment comparative efficacy
Does lidocaine work? Positive signals exist, but evidence is very low quality (Derry 2014, PMID 25058164) A sufficiently powered, credible-blind pragmatic RCT
Does topical treatment preserve sensation? No 12-week deterioration in the PDN capsaicin RCT (Simpson 2017, PMID 27746370) Repeated exposure over years in insensate diabetic feet

Selection

Localized superficial pain, allodynia and limited systemic tolerance favor topical trials. Broken skin and diffuse/deep pain do not.

Blocks

Diagnostic blocks are temporary perturbations, not definitive mechanism tests; spread, sedation and expectation confound response (Mailis 2012, PMID 22606679).

A response is interpretable only when target, injectate, volume, image guidance, sensory change, pain trajectory and co-administered sedation are documented. False-positive responses can arise through anesthetic spread or expectation; false-negative responses through incomplete target coverage. Consequently, a single block should not be treated as a binary assay of whether a nerve “causes” chronic pain (Mailis 2012, PMID 22606679).

PHN procedures

Reviews cover epidural, paravertebral, sympathetic and pulsed-radiofrequency approaches, but heterogeneity and bias limit rankings (Lin 2019, PMID 31151330).

Botulinum toxin

Selected peripheral trials support a later-line option, but injection technique and phenotype remain unsettled (Moisset 2020, PMID 32276788).

BOTNEP randomized 68 patients to two administrations 12 weeks apart; 66 entered the primary analysis. Botulinum toxin A reduced mean weekly pain across 24 weeks by an adjusted 0.77/10 versus placebo (95% CI 0.59–0.95; P<0.0001). Injection pain occurred in 56% with toxin and 53% with placebo; allodynia and limited thermal deficit were proposed, not validated, as response predictors (Attal 2016, PMID 26947719).

This evidence supports a selected later-line option, not a generic injection pathway. The injections are numerous, dose and grid vary, masking may be compromised by weakness or local effects, and evidence outside focal peripheral neuropathic pain is sparse (Moisset 2020, PMID 32276788).

Procedure table

Option Target Principal harm
Lidocaine patch Superficial ectopic input Skin reaction
Capsaicin 8% TRPV1 terminals Application pain
Nerve block Named nerve Bleeding/infection/nerve injury
Epidural Root/inflammation Dural/vascular/infectious risk
Radiofrequency Nerve/ganglion Neuritis/deafferentation
Botulinum toxin Peripheral terminals Weakness/injection harm

Procedure-specific evidence thresholds

Procedure Comparator needed Minimum durability Safety outcome that must be counted
Peripheral nerve block Saline or credible active control where feasible Beyond anesthetic duration Nerve injury, vascular puncture, infection, systemic local-anesthetic toxicity
Epidural injection Sham/active procedural comparator At least 3–6 months Dural puncture, infection, bleeding, neurologic injury
Pulsed radiofrequency Credible sham with sensory masking assessment At least 6 months Neuritis, dysesthesia, motor deficit and repeat procedures
Botulinum toxin A Saline injections with masking check Full dosing interval and repeat cycle Injection pain, focal weakness and spread
Capsaicin 8% Low-dose/vehicle patch with application-pain masking analysis Through retreatment interval Burns, prolonged sensory change and diabetic-foot events

Evidence threshold

Require sham or credible control, responder outcomes, durability, function and adverse events. Case series cannot establish net benefit.

Evidence interpretation map

The table makes the evidence role and inferential boundary explicit; it is not a replacement for the full reports.

PMID Year Evidence role What it cannot establish alone
25058164 2014 Systematic review defining lidocaine evidence weakness That lidocaine is ineffective in every localized phenotype
28085183 2017 Cross-etiology capsaicin responder synthesis Comparative long-term effectiveness
27746370 2017 Large placebo-controlled PDN capsaicin trial Benefit from repeated applications over years
26947719 2016 Repeated-injection botulinum toxin RCT Validated response phenotype or broad etiologic generalization
22606679 2012 Interventional guideline and evidence boundary Diagnostic accuracy of a block as a mechanism test
34554688 2021 Direct capsaicin-versus-pregabalin patient-reported outcomes Blinded comparative superiority

Explicit controversies

  1. Safety-first placement of lidocaine. Some guidelines retain topical lidocaine because systemic exposure is low, while systematic review evidence is very low quality (Derry 2014, PMID 25058164); (Attal 2010, PMID 20402746). The disagreement reflects different weighting of evidence certainty and harm, not different reading of a large definitive trial.
  2. Capsaicin mean effect versus responder value. The average placebo-adjusted PDN difference is modest (Simpson 2017, PMID 27746370), yet a treatment applied once can be valuable to an individual responder who cannot tolerate systemic medication. Mean change, ≥30%/≥50% response and duration should therefore be shown together.
  3. Botulinum toxin signal versus implementation maturity. BOTNEP reports a precise 0.77-point advantage (Attal 2016, PMID 26947719), but technique, dose, anatomical grid and response phenotype remain insufficiently standardized for first-line use.
  4. Blocks as prediction. Temporary analgesia is often used to justify durable procedures, although injectate spread and expectancy prevent a block from being a validated treatment-selection biomarker (Mailis 2012, PMID 22606679).

Minimum reporting controls

Domain Required report
Case definition Possible, probable or definite neuropathic pain
Etiology Lesion/disease and diagnostic evidence
Distribution Focal, length-dependent, dermatomal, at-level or below-level
Baseline phenotype Negative and positive sensory signs
Comparator Placebo/sham, active care or natural history
Exposure Dose, duration, adherence and co-interventions
Benefit Mean change plus ≥30% and ≥50% responders where applicable
Function Sleep, mobility, participation and patient global change
Harm Adverse events, withdrawals and serious events
Durability Follow-up after treatment and attrition
Subgroups Prespecified interaction test, not within-group significance
Missingness Denominator and imputation method

Reporting cautions

  • Do not infer lesion presence from a symptom descriptor.
  • Do not convert a group-average association into an individual diagnostic rule.
  • Do not treat statistical significance as clinically important benefit.
  • Do not compare NNTs without checking outcome threshold, duration and population.
  • Do not interpret an inactive or completed registry record as proof of efficacy.
  • Do not merge painful and painless neuropathy outcomes.
  • Do not omit adverse-event withdrawals from responder interpretation.
  • Do not call a post hoc subgroup predictive without an interaction test.
  • Do not generalize a focal peripheral result to central neuropathic pain.
  • State when evidence is short-term, indirect or restricted to a selected cohort.

Open questions

  • Which sensory phenotype predicts topical response?
  • Do blocks predict durable procedures?
  • What is long-term repeated-capsaicin safety?
  • Which PHN procedure merits a definitive sham trial?

References

  1. Finnerup NB, Attal N, Haroutounian S, et al.. Pharmacotherapy for neuropathic pain in adults: a systematic review and meta-analysis. Lancet Neurol. 2015;14:162-73. PMID 25575710
  2. Derry S, Wiffen PJ, Moore RA, et al.. Topical lidocaine for neuropathic pain in adults. Cochrane Database Syst Rev. 2014;2014:CD010958. PMID 25058164
  3. Derry S, Rice AS, Cole P, et al.. Topical capsaicin (high concentration) for chronic neuropathic pain in adults. Cochrane Database Syst Rev. 2017;1:CD007393. PMID 28085183
  4. Mailis A, Taenzer P. Evidence-based guideline for neuropathic pain interventional treatments: spinal cord stimulation, intravenous infusions, epidural injections and nerve blocks. Pain Res Manag. 2012;17:150-8. PMID 22606679
  5. Lin CS, Lin YC, Lao HC, et al.. Interventional Treatments for Postherpetic Neuralgia: A Systematic Review. Pain Physician. 2019;22:209-228. PMID 31151330
  6. Moisset X, Bouhassira D, Avez Couturier J, et al.. Pharmacological and non-pharmacological treatments for neuropathic pain: Systematic review and French recommendations. Rev Neurol (Paris). 2020;176:325-352. PMID 32276788
  7. Derry S, Wiffen PJ, Kalso EA, et al.. Topical analgesics for acute and chronic pain in adults - an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2017;5:CD008609. PMID 28497473
  8. Burness CB, McCormack PL. Capsaicin 8 % Patch: A Review in Peripheral Neuropathic Pain. Drugs. 2016;76:123-34. PMID 26666418
  9. Giaccari LG, Aurilio C, Coppolino F, et al.. Capsaicin 8% Patch and Chronic Postsurgical Neuropathic Pain. J Pers Med. 2021;11. PMID 34683101
  10. Olusanya A, Yearsley A, Brown N, et al.. Capsaicin 8% Patch for Spinal Cord Injury Focal Neuropathic Pain, a Randomized Controlled Trial. Pain Med. 2023;24:71-78. PMID 35799365
  11. Brix Finnerup N, Hein Sindrup S, Staehelin Jensen T. Management of painful neuropathies. Handb Clin Neurol. 2013;115:279-90. PMID 23931787
  12. van Nooten F, Treur M, Pantiri K, et al.. Capsaicin 8% Patch Versus Oral Neuropathic Pain Medications for the Treatment of Painful Diabetic Peripheral Neuropathy: A Systematic Literature Review and Network Meta-analysis. Clin Ther. 2017;39:787-803.e18. PMID 28365034
  13. Felemban A, Allan S, Youssef E, et al.. Lidocaine patch for treatment of acute localized pain in the emergency department: a systematic review and meta-analysis. Eur J Emerg Med. 2024;31:413-422. PMID 38985833
  14. Attal N, Cruccu G, Baron R, et al.. EFNS guidelines on the pharmacological treatment of neuropathic pain: 2010 revision. Eur J Neurol. 2010;17:1113-e88. PMID 20402746
  15. Moisset X. Neuropathic pain: Evidence based recommendations. Presse Med. 2024;53:104232. PMID 38641202
  16. Attal N, Bouhassira D, Colvin L. Advances and challenges in neuropathic pain: a narrative review and future directions. Br J Anaesth. 2023;131:79-92. PMID 37210279
  17. Snedecor SJ, Sudharshan L, Cappelleri JC, et al.. Systematic review and meta-analysis of pharmacological therapies for pain associated with postherpetic neuralgia and less common neuropathic conditions. Int J Clin Pract. 2014;68:900-18. PMID 24698515
  18. Hsieh YL, Chen HY, Lin CR, et al.. Efficacy of epidural analgesia for intractable cancer pain: A systematic review. Pain Pract. 2023;23:956-969. PMID 37455298
  19. Forero M, Adhikary SD, Lopez H, et al.. The Erector Spinae Plane Block: A Novel Analgesic Technique in Thoracic Neuropathic Pain. Reg Anesth Pain Med. 2016;41:621-7. PMID 27501016
  20. Knezevic NN, Jovanovic F, Candido KD, et al.. Oral pharmacotherapeutics for the management of peripheral neuropathic pain conditions - a review of clinical trials. Expert Opin Pharmacother. 2020;21:2231-2248. PMID 32772737
  21. Kontor EK, Wellan C, Maaz HM, et al.. Emerging Therapeutic Modalities and Pharmacotherapies in Neuropathic Pain Management: A Systematic Review and Meta-Analysis of Parallel Randomized Controlled Trials. Pain Res Manag. 2024;2024:6782574. PMID 39748928
  22. Bouchenaki H, Bégou M, Magy L, et al.. [Pharmacological management of neuropathic pain]. Therapie. 2019;74:633-643. PMID 31097329
  23. Andrews JC. Vulvodynia interventions--systematic review and evidence grading. Obstet Gynecol Surv. 2011;66:299-315. PMID 21794194
  24. Moisset X, Bouhassira D, Attal N. French guidelines for neuropathic pain: An update and commentary. Rev Neurol (Paris). 2021;177:834-837. PMID 34332778
  25. Thouaye M, Yalcin I. Neuropathic pain: From actual pharmacological treatments to new therapeutic horizons. Pharmacol Ther. 2023;251:108546. PMID 37832728
  26. Simpson DM, Robinson-Papp J, Van J, et al. Capsaicin 8% patch in painful diabetic peripheral neuropathy: a randomized, double-blind, placebo-controlled study. J Pain. 2017;18:42-53. PMID 27746370
  27. Attal N, de Andrade DC, Adam F, et al. Safety and efficacy of repeated injections of botulinum toxin A in peripheral neuropathic pain (BOTNEP): a randomised, double-blind, placebo-controlled trial. Lancet Neurol. 2016;15:555-565. PMID 26947719
  28. Viel E, Eerdekens M, Kandaswamy P. Treatment impact on patient-reported outcomes in peripheral neuropathic pain: comparing single intervention with topical high-concentration capsaicin to daily oral pregabalin. Pain Physician. 2021;24:453-463. PMID 34554688